gMG Connect
  • Saved

4mo
The Role of Complement in the Pathogenesis and Treatment of Myasthenia Gravis - PubMed

The Role of Complement in the Pathogenesis and Treatment of Myasthenia Gravis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/40422242/

Myasthenia gravis is an antibody-mediated autoimmune condition characterized by defects in cholinergic transmission at the neuromuscular junction. In AchR antibody-positive patients, complement activation plays a prominent role in the disease...

Complement activation drives neuromuscular junction damage in AChR-positive myasthenia gravis. Targeting complement pathways, including C5 inhibition, offers effective therapeutic strategies, with emerging agents expanding treatment options in autoimmune neuromuscular disease.

  • Saved

4mo
American Academy of Neurology Annual Meeting

The 2026 American Academy of Neurology (AAN) Annual Meeting is taking place from April 18 to 22 in Chicago and virtually. The conference features more than 3,500 abstracts highlighting the latest groundbreaking research in neurology.

Click to access a summary of the content from day one.

  • Saved

4mo
Background Image DesktopBackground Image Mobile

A case of small cell lung cancer treated with immunotherapy revealed anti-Hu–associated limbic encephalitis, presenting with cognitive and behavioral symptoms. Findings underscore the risk of immune-mediated neurological syndromes in SCLC, warranting early recognition and intervention.

Recognize rare neurological risks in SCLC

  • Saved

4mo
Preview Into American Academy of Neurology Annual Meeting 2026

The annual meeting of the American Academy of Neurology (AAN) is being held from April 18 to 22, 2026, in Chicago and online.

The global neurology community gathers each year for the AAN Annual Meeting for five days of diverse learning opportunities covering all neurology topics and subspecialties, allowing attendees to stay up-to-date on the latest science and education.

Click above for an exclusive preview of this year's conference! 

  • Saved

4mo
Novel Therapies for Generalized Myasthenia Gravis: Insights Into FcRn and Complement Inhibition - PubMed

Novel Therapies for Generalized Myasthenia Gravis: Insights Into FcRn and Complement Inhibition - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41505161/

These therapies offer personalized, effective options for MG management, though challenges in cost and access remain. Future research should address long-term outcomes and biomarkers.

Review highlights FcRn and complement inhibitors in generalized myasthenia gravis, demonstrating improved clinical outcomes, rapid efficacy in refractory disease, and evolving personalized treatment approaches despite safety, cost, and access challenges.